Use of the ferritin/alanine aspartate transaminase ratio as an iron overload marker independent of liver cell damage.
To define an iron overload index independent of liver cell damage, the mean annual levels of alanine aspartate transaminase (ALAT) and serum ferritin and their ratios were determined. Ferritin/ALAT ratio values were compared between two groups of patients with acute or chronic hepatitis without iron overload, and one group of thalassaemic patients with iron overload. The two groups without iron overload exhibited ferritin/ALAT ratio values of 2 and 1.2 respectively; a ratio value higher than 10 was always observed in those patients with iron overload. The ferritin/ALAT ratio is correlated with the degree of iron overload. This ratio increases in regularly-transfused patients without chelation treatment. It generally remains stable or decreases after initiation of iron chelation therapy. The ferritin/ALAT ratio thus appears useful in the follow-up of patients subjected to a long-term transfusional treatment particularly when acute or chronic liver cell damage may interfere with iron overload by increasing serum ferritin values.
Triadou
P
P
Laboratorie d'Hématologie, Hôpital Necker-Enfants Malades, Paris, France.
Regnat-Lusinchi
A
A
Girot
R
R
D000410:Alanine Transaminase / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000008:administration & dosage; D005293:Ferritins / Q000097:blood*; D006467:Hemophilia A / Q000097:blood / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000628:therapy; D006801:Humans; D007501:Iron / Q000097:blood*; D008107:Liver Diseases / Q000097:blood*; D013789:Thalassemia / Q000097:blood / Q000628:therapy
D015415:Biomarkers; D005293:Ferritins; D007501:Iron; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003676:Deferoxamine